MHE Staff

Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.

This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.

Kelsay is the President and CEO of the Business Group on Health. She predicts that in 2024, employers will "sound the drug price alarm."

Robert E. White Jr. is the President of The Doctors Company. He believes "social inflation will affect malpractice insurers."

This year's top oncology news included a study that suggested low-fat meals could affect blood concentration levels, and high blood concentration has been associated with a better response to the drug, Alecensa.

Weight-loss medications were very much in the news this year, and the pages and website of Managed Healthcare Executive were no exception. Articles on off-label use of the GLP-1s such as Ozempic (semaglutide) and the FDA approval of Zepbound (tirzepatide) garnered the most page views.

Articles about Humira biosimilars, over-the-counter hearing aids and specialty drugs were among those about healthcare and drug costs that had the most pageviews on the MHE website in 2023.

News about state bans on accumulators, Pfizer’s announcements about vaccines and cardiovascular deaths increasing because of climate change were the most viewed news items on the Managed Healthcare Executive website this year.

Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.

IDose TR will be available in first quarter of 2024 with a wholesale acquisition cost of $13,950 per dose/implant.

Rising healthcare costs impact their own organization’s competitiveness, said those who responded to the Pulse of the Purchaser survey by the National Alliance of Healthcare Purchaser Coalitions.

Mike Tuffin is set to become AHIP's President and CEO from January 8, 2024, succeeding Julie Simon Miller.

Marstacimab is being reviewed to prevent or reduce the frequency of bleeding episodes in people with hemophilia A or B. The FDA has set an action date in the first quarter of 2024.

Joe Kvedar, M.D., the immediate past chair of the association, is chairing the 35-member group that will be focused on eliminating barriers to telehealth and other types of virtual health.

In response to the high demand for healthcare professionals and over 2 million annual job openings — a 40% growth rate surpassing the average for all other occupations—healthcare organizations are seeking technological solutions to address this pressing issue.

If approved, elafibranor would be a second-line treatment for patients with primary biliary cholangitis. The Prescription Drug User Fee Act action date is June 10, 2024.

Acoramidis is an oral small molecule to treat patients with transthyretin amyloid cardiomyopathy.

Pharmacy benefit managers have been under pressure to simplify their complicated, obscure pricing tactics.

The survey highlights a growing willingness among employees to pay for premium lens options and a focus on early diagnosis of eye conditions, aligning with the broader trend of holistic well-being.

Cigna has been looking to sell its Medicare Advantage business, perhaps as a way to fend off antitrust objection to the deal.

CTTP is rare hereditary blood clotting disorder stemming from a disease-causing mutation in the ADAMTS13 gene. This gene plays a crucial role in producing the ADAMTS13 enzyme, responsible for regulating blood clotting.

Although the CDC predicted a decline in basic Medicare Part D premiums for 2024 due to the IRA, a recent report revealed an increase in premiums for Medicare Part D prescription drug plans in California, Florida, New York, Pennsylvania and Texas.

After two years of use, the twice-yearly Sunlenca remains active against HIV in patients with multi-drug resistant disease.

Topline results from week 16 of a phase 3b trial demonstrated the efficacy and safety of Tremfya across all skin tones.

Velsipity is the second S1P receptor modulator approved by the FDA to treat patients with moderate-to-severe ulcerative colitis. The wholesale acquisition cost is $6,164 for a 30-day supply.

The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.

The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.

The dosage of Zoryve for children 6 to 11 is the same as for those over the age of 12. The list price is same for both pediatrics and adults — $825 per tube.

In a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.

Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.